Immunosuppressants in Behcet’s disease: a boon or a bane?
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20222145Keywords:
Adalimumab, TNFα inhibitors, Behcet’s disease, Tuberculosis, ImmunosuppressionAbstract
Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by antagonising tumour necrosis factor-alpha prescribed in many rheumatological conditions like Rheumatic arthritis, Ankylosing spondylitis and Behcet’s disease. Serious side effects with this drug include heart and liver failure, nervous and blood disorders, allergic and immune system reactions and opportunistic infections. A 27-year-old female patient, known case of Behcet’s disease presented to the hospital with complaints of fever, cough and breathlessness following administration of Adalimumab, six doses over three months. Chest X-ray and BAL-CBNAAT was suggestive of Tuberculosis. AKT was started and Adalimumab was suspended until patient recover.
Metrics
References
Akman-Demir G, Saip S, Siva A. Behcet’s disease. Curr Treat Neurol. 2011;13(3):290-310.
Kedia S, Mouli VP, Kamat N, Sankar J, Ananthakrishnan A, Makharia G, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. J Am College Gastroenterol. 2020;115(3):340-9.
Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med. 2019;40(4):721-39.
Türsen Ü. Pathophysiology of the Behcet's Disease. Pathol Res Int. 2012;2012:45-9.
Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immuno-suppression. Rheumatol Int. 2011;31(3):327-37.
Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol. 2005;4(2):189-94.
Vandermarliere A, Audenhove AV, Peetermans WE, Vanrenterghem Y, Maes B. Mycobacterial infection after renal transplantation in a Western population. Transplant Infect Dis. 2003;5(1):9-15.
Patil S, Jadhav A. Short course of high-dose steroids for anaphylaxis caused flare up of tuberculosis: a case report. J Translat Int Med. 2019;7(1):39-42.
Jiang JR, Yen SY, Wang JY. Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients. Respirology. 2011; 16(2):308-13.
Downloads
Published
How to Cite
Issue
Section
